Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
Read full article
Oops!
SARS-CoV-2 Variant Booster Program Update
: Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants
TeenCOVE Study Update
: Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date
2021 and 2022 Vaccine Manufacturing: Company increased its 2021 supply forecast to between 800 million and 1 billion doses; Company making investments to increase global supply for COVID-19 Vaccine to up to 3 billion doses in 2022
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Published: Jan 11, 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date. This announcement reflects the Company’s commitment to accelerating its infectious disease portfolio based on Moderna’s experience with its COVID-19 vaccine. The development programs announced today are mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. Moderna also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.